| RXRA Protein | |
|---|---|
| Protein Name | RXRA Protein |
| Gene Symbol | RXRA |
| UniProt ID | P19793 |
| PDB Structures | 1R0N, 3A0E, 4NQM |
| Molecular Weight | 50 kDa |
| Subcellular Localization | Nucleus |
| Protein Family | Nuclear Receptor Family |
RXRA is a protein involved in cellular signaling and transcriptional regulation.[1] This protein plays important roles in regulating gene expression and cellular signaling.[2] In the context of neurodegenerative diseases, RXRA is implicated in Alzheimer's disease, Parkinson's disease, and other disorders through various mechanisms.[3]
RXRA has a typical nuclear receptor structure: an N-terminal AF-1 domain, a DNA-binding domain (DBD) with two zinc fingers, a hinge region, and a ligand-binding domain (LBD). RXRA binds 9-cis retinoic acid as a ligand. RXRA forms heterodimers with other nuclear receptors including PPARs, VDR, TR, and RARs. The protein binds DNA as a heterodimer to various response elements. RXRA has a unique C-terminal AF-2 domain involved in coactivator recruitment.
RXRA is a nuclear receptor that functions as a master regulator of nuclear receptor signaling. It is a ligand-activated transcription factor that binds 9-cis retinoic acid. RXRA plays crucial roles in development, cell differentiation, metabolism, and homeostasis. It forms heterodimers with other nuclear receptors, enabling them to bind DNA and regulate gene expression. RXRA is essential for the function of many nuclear receptor pathways including PPAR, VDR, TR, and RAR signaling.
RXRA is implicated in neurodegenerative diseases through its role in nuclear receptor signaling. In Alzheimer's disease, RXRA is involved in retinoic acid signaling affecting neuronal survival. Dysregulation of retinoid signaling is implicated in AD pathogenesis. In Parkinson's disease, RXRA influences dopaminergic neuron survival. RXRA heterodimerizes with PPARA and other receptors relevant to neurodegeneration. Targeting RXRA/nuclear receptor pathways is being explored for neurotherapeutics.
Retinoids (RXRA ligands) are being explored for cancer therapy and neuroprotection. In neurodegeneration, retinoid therapy may have beneficial effects. However, systemic retinoid use has significant side effects. Selective modulators that specifically target RXRA in the brain are being developed. Gene therapy approaches to modulate RXRA signaling are also being investigated. RXRA represents a master regulator that could be targeted for neuroprotection.